StreetInsider.com News Articles

Alcon acquires Neurotech for $550M, adding rare eye disease drug

Tue, 20 Oct 2026 16:35:17 -0400

Alcon (SIX/NYSE: ALC) has acquired Neurotech Pharmaceuticals, Inc. for $550 million, gaining ownership of ENCELTO, the first FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel), a rare retinal disease that causes progressive central vision loss.

The FDA approved ENCELTO in March 2025 under a Biologics License Application, granting it priority review status and Orphan Drug designation. The therapy is an encapsulated cell implant surgically placed in the eye that continuously releases recombinant human ciliary neurotrophic factor (rhCNTF), a protein intended to protect light-sensing cells in the retina. It is currently available only in the U.S.

An estimated 25,000 patients in the U.S.

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Tue, 20 Oct 2026 16:35:00 -0400

Expands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease
Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access
Broadens Alcon’s offering in retinal disease

GENEVA--(BUSINESS WIRE)-- Regulatory News:

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases.

This acquisition expands Alcon's retina portfolio with ENCELTO™ (revakinagene taroretcel-lwey), the

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Tue, 20 Oct 2026 16:35:00 -0400

Expands Alcon’s retina portfolio with ENCELTO, an encapsulated cell therapy intended for surgical implantation in the eye for patients with MacTel Type 2, a rare retinal disease
Alcon's established presence and expertise in surgical retina is expected to accelerate commercialization and patient access
Broadens Alcon’s offering in retinal disease

GENEVA--(BUSINESS WIRE)-- Regulatory News:

This acquisition expands Alcon's retina portfolio with ENCELTO™ (revakinagene taroretcel-lwey), the

Algoma Central Corporation to Release Third Quarter 2026 Results on November 6, 2026; Announces Preliminary Results

Tue, 20 Oct 2026 07:00:00 -0400

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- Algoma Central Corporation (TSX: ALC) ("Algoma" or the "Company") today announced preliminary, unaudited financial results for the three and nine months ended September 30, 2026.

Based on preliminary results, Algoma expects to report the following for the third quarter of 2026:

Revenue of approximately $288 million, compared to $228 million in the third quarter of 2025;
Net earnings of approximately $54 million, compared to $39 million in the third quarter of 2025;
Basic and diluted earnings per share of approximately $1.34, compared to $0.97 in the third quarter of 2025; and
EBITDA1 of approximately $95 million, compared

Algoma Central Corporation to Release Third Quarter 2026 Results on November 6, 2026; Announces Preliminary Results

Tue, 20 Oct 2026 07:00:00 -0400

Based on preliminary results, Algoma expects to report the following for the third quarter of 2026:

Revenue of approximately $288 million, compared to $228 million in the third quarter of 2025;
Net earnings of approximately $54 million, compared to $39 million in the third quarter of 2025;
Basic and diluted earnings per share of approximately $1.34, compared to $0.97 in the third quarter of 2025; and
EBITDA1 of approximately $95 million, compared

FDA approves Alcon eye drops for up to 12 hours of redness relief

Fri, 16 Oct 2026 15:57:18 -0400

Alcon (SIX/NYSE: ALC) announced that the U.S. Food and Drug Administration has approved BRYTLY Redness Reliever Eye Drops, a new over-the-counter product the company says reduces eye redness with results lasting up to 12 hours per dose.

According to the company, one drop begins working within one minute. The product's label claims a duration of up to 12 hours, compared to up to 8 hours listed on the label of Bausch + Lomb's Lumify, a competing redness-relief drop.

Alcon states that BRYTLY contains no bleaches or dyes and has been clinically shown to carry a low risk of redness rebound and tachyphylaxis

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Fri, 16 Oct 2026 15:57:00 -0400

One drop works to significantly reduce redness, with results lasting up to 12 hours1
Lasts up to 50% longer than Lumify1-2,*
Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that the U.S. Food and Drug Administration (FDA) has approved BRYTLY® Redness Reliever Eye Drops. With one drop, BRYTLY works in just one minute to significantly reduce redness and delivers up to 12 hours of whiter, brighter-looking

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Fri, 16 Oct 2026 15:57:00 -0400

One drop works to significantly reduce redness, with results lasting up to 12 hours1
Lasts up to 50% longer than Lumify1-2,*
Expands Alcon's portfolio of consumer eye care solutions and will be available in major retailers nationwide and online in the coming months

Increasing unusual option volume: JBS CCC AIPO INDA CMBT ERIC ALC

Thu, 15 Oct 2026 10:31:28 -0400

Increasing unusual option volume: JBS CCC AIPO INDA CMBT ERIC ALC

Algoma Central Corporation Increases Quarterly Dividend and Declares Special Dividend

Wed, 07 Oct 2026 07:00:00 -0400

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- Algoma Central Corporation (“Algoma”, the “Company”) (TSX: ALC) today announced that its Board of Directors (the “Board”) has increased the Company’s regular quarterly dividend by $0.10 per common share, or approximately 48%, to $0.31 per common share from $0.21 per common share. The Board has also declared a special dividend of $1.00 per common share.

The regular quarterly dividend of $0.31 per common share will be paid on December 1, 2026, to shareholders of record at the close of business on November 17, 2026.

In addition, the special dividend of $1.00 per common share will

Algoma Central Corporation Increases Quarterly Dividend and Declares Special Dividend

Wed, 07 Oct 2026 07:00:00 -0400

The regular quarterly dividend of $0.31 per common share will be paid on December 1, 2026, to shareholders of record at the close of business on November 17, 2026.

In addition, the special dividend of $1.00 per common share will

Barclays Starts Alcon Inc. (ALC) at Equalweight

Wed, 07 Oct 2026 03:42:00 -0400

Barclays analyst Christopher Pasquale initiates coverage on Alcon Inc. (NYSE: ALC) with a Equalweight rating and a price target of $70.00.

For an analyst ratings summary and ratings history on Alcon Inc. click here. For more ratings news on Alcon Inc. click here.

Shares of Alcon Inc. closed at $63.19 yesterday.

Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief

Mon, 28 Sep 2026 10:15:00 -0400

Formulated with hyaluronic acid, Systane® PRO PRESERVATIVE-FREE instantly hydrates dry eyes1
Systane® PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes2-4
The latest addition to the #1 global consumer brand of artificial tears5 is now available in Canada

TORONTO--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of Systane® PRO Preservative-Free (PF) in Canada as Systane’s most advanced formula. Systane PRO PF is the longest lasting dry eye symptom relief eye drop for all types of dry eye in

Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief

Mon, 28 Sep 2026 10:15:00 -0400

Formulated with hyaluronic acid, Systane® PRO PRESERVATIVE-FREE instantly hydrates dry eyes1
Systane® PRO PF is a multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes2-4
The latest addition to the #1 global consumer brand of artificial tears5 is now available in Canada

Alcon launches Unity M ophthalmic microscope in U.S. and Japan

Thu, 03 Sep 2026 09:01:13 -0400

Alcon (NYSE: ALC) has announced the initial commercial launch of the Unity M, a premium surgical microscope for ophthalmic surgeons, with rollout beginning in the U.S. and Japan, followed by Europe.

The Unity M is the third product added to Alcon's Unity platform, joining the Unity VCS and Unity CS. The device has received regulatory approvals in the U.S., Japan, Canada, India, and Europe, with inventory beginning to ship in September.

The base model includes three core visualization features. The first is a red reflex zone that Alcon claims is up to six times larger than the Zeiss ARTEVO, based on laboratory

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Thu, 03 Sep 2026 09:00:00 -0400

Features industry-leading red reflex for stable, consistent visualization and Color Tunable Illumination for improved surgical precision1,2,*,†
Latest addition to the UNITY platform that allows for modular upgrades in the future, customized to surgeon preferences3
UNITY M will begin its commercial rollout in the U.S. and Japan later this year with additional markets to follow

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the initial commercial launch of UNITY® M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Thu, 03 Sep 2026 09:00:00 -0400

Features industry-leading red reflex for stable, consistent visualization and Color Tunable Illumination for improved surgical precision1,2,*,†
Latest addition to the UNITY platform that allows for modular upgrades in the future, customized to surgeon preferences3
UNITY M will begin its commercial rollout in the U.S. and Japan later this year with additional markets to follow

Alcon prices €500M senior notes due 2033

Wed, 26 Aug 2026 17:00:13 -0400

Alcon Inc. (SIX/NYSE: ALC) has priced a public offering of €500 million in aggregate principal amount of 3.875% senior notes due 2033, according to a company statement.

The notes will be issued by Alcon Finance Corporation, an indirect wholly owned subsidiary of Alcon Inc., and will be fully and unconditionally guaranteed on a senior basis by Alcon Inc.

Alcon has applied to have the notes admitted to the official list of the Luxembourg Stock Exchange and to trading on the Euro MTF market.

The offering is expected to close on September 2, 2026, subject to customary closing conditions.

Alcon said it intends to use

Alcon prices €500M senior notes due 2033

Wed, 26 Aug 2026 17:00:13 -0400

Alcon Inc. (SIX/NYSE: ALC) has priced a public offering of €500 million in aggregate principal amount of 3.875% senior notes due 2033, according to a company statement.

The notes will be issued by Alcon Finance Corporation, an indirect wholly owned subsidiary of Alcon Inc., and will be fully and unconditionally guaranteed on a senior basis by Alcon Inc.

Alcon has applied to have the notes admitted to the official list of the Luxembourg Stock Exchange and to trading on the Euro MTF market.

The offering is expected to close on September 2, 2026, subject to customary closing conditions.

Alcon said it intends to use

Alcon prices €500M senior notes due 2033

Wed, 26 Aug 2026 17:00:13 -0400

Alcon Inc. (SIX/NYSE: ALC) has priced a public offering of €500 million in aggregate principal amount of 3.875% senior notes due 2033, according to a company statement.

The notes will be issued by Alcon Finance Corporation, an indirect wholly owned subsidiary of Alcon Inc., and will be fully and unconditionally guaranteed on a senior basis by Alcon Inc.

Alcon has applied to have the notes admitted to the official list of the Luxembourg Stock Exchange and to trading on the Euro MTF market.

The offering is expected to close on September 2, 2026, subject to customary closing conditions.

Alcon said it intends to use

Alcon prices €500M senior notes due 2033

Wed, 26 Aug 2026 17:00:13 -0400

Alcon Inc. (SIX/NYSE: ALC) has priced a public offering of €500 million in aggregate principal amount of 3.875% senior notes due 2033, according to a company statement.

The notes will be issued by Alcon Finance Corporation, an indirect wholly owned subsidiary of Alcon Inc., and will be fully and unconditionally guaranteed on a senior basis by Alcon Inc.

Alcon has applied to have the notes admitted to the official list of the Luxembourg Stock Exchange and to trading on the Euro MTF market.

The offering is expected to close on September 2, 2026, subject to customary closing conditions.

Alcon said it intends to use

Alcon Prices EUR 500 Million Senior Notes Offering

Wed, 26 Aug 2026 17:00:00 -0400

GENEVA--(BUSINESS WIRE)-- Alcon Inc. (SIX/NYSE: ALC), today announced that it has commenced and priced a public offering of EUR 500 million aggregate principal amount of its 3.875% senior notes due 2033 (the “Notes”). The Notes will be issued by Alcon Finance Corporation, Alcon Inc.’s indirect wholly owned subsidiary, and will be fully and unconditionally guaranteed on a senior basis by Alcon Inc.

Application has been made for the Notes to be admitted to the official list of the Luxembourg Stock Exchange and for the Notes to be admitted to trading on the Euro MTF.

The offering is expected to

Alcon Prices EUR 500 Million Senior Notes Offering

Wed, 26 Aug 2026 17:00:00 -0400

Application has been made for the Notes to be admitted to the official list of the Luxembourg Stock Exchange and for the Notes to be admitted to trading on the Euro MTF.

The offering is expected to

Alcon Prices EUR 500 Million Senior Notes Offering

Wed, 26 Aug 2026 17:00:00 -0400

Application has been made for the Notes to be admitted to the official list of the Luxembourg Stock Exchange and for the Notes to be admitted to trading on the Euro MTF.

The offering is expected to

Alcon Prices EUR 500 Million Senior Notes Offering

Wed, 26 Aug 2026 17:00:00 -0400

Application has been made for the Notes to be admitted to the official list of the Luxembourg Stock Exchange and for the Notes to be admitted to trading on the Euro MTF.

The offering is expected to